Here are seven biopharma-related trends for 2026 that have emerged from GEN interviews with experts and other industry stakeholders, and from reviews of reports and public statements.

AI can help design AI systems: automating architecture choices, discovering algorithms, and optimizing hardware ...

Cathie Wood’s ARK Investment Management sharply increased its exposure to AI-driven biotechnology and cryptocurrency during ...

Recursion Pharmaceuticals (RXRX) just delivered encouraging Phase 1b/2 TUPELO data for its FAP drug candidate REC-4881, and that clinical update has quickly reshaped how both Wall Street and ...

For many, the festive season conjures images of cosy gatherings, twinkling lights and joyful celebration. But beneath the ...

Abstract: Approximate computing, frequently used in error tolerant applications, aims to achieve higher circuit performances by allowing the possibility of inaccurate ...

This classic indoor exercise machine has some tricks up its sleeve. Here are four workouts, for runners and walkers, to get ...

Innovation fails when every pilot starts from scratch; the chassis approach shows how to move fast with vendors while keeping ...

RXRX Stock jumps after JPMorgan upgrade and trial data boost, fueling investor optimism in Recursion’s AI drug discovery ...

Vision Marine Technologies Announces Pricing of Public Offering of 32M Units; Expects Gross Proceeds of $9.6M; Offering Expected to Close Dec. 19; Plans to Use Proceeds for General Corporate Purposes, ...

Recursion Pharmaceuticals, Inc. (RXRX) recently received a notable upgrade from JP Morgan analyst Eric Joseph, who shifted his rating to “Overweight” o7, 2025. This upgrade comes as the stock trades ...

Patronus AI unveiled “Generative Simulators,” adaptive “practice worlds” that replace static benchmarks with dynamic ...